DOCSLIB.ORG

ASN Kidney Week 2019

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
ASN Kidney Week 2019 ONSITE GUIDE 20 19 Washington, DC Nov. 5–10 CORPORATE SUPPORTERS The ASN Corporate Support Program recognizes supporters year round for their generous contributions to the Society. Through this program, supporters help ASN lead the fight against kidney diseases. ASN gratefully acknowledges the following companies and organizations for their contributions in 2019. DIAMOND LEVEL PLATINUM LEVEL GOLD LEVEL Akebia Therapeutics OPKO Pharmaceuticals, LLC Amgen Retrophin, Inc. Janssen Pharmaceuticals, Inc. BRONZE LEVEL Amicus Therapeutics KDIGO Cara Therapeutics Rockwell Medical Daiichi Sankyo, Inc. Sanofi Genzyme GSK As of August 19, 2019 TABLE OF CONTENTS Kidney Week Mobile App 3 Schedule-at-a-Glance 4 Welcome 6 Accreditation, CE Credits, MOC Points 7 Certificates of Attendance for International Participants 8 Day-at-a-Glance: Tuesday, November 5 10 Day-at-a-Glance: Wednesday, November 6 12 Day-at-a-Glance: Thursday, November 7 14 Day-at-a-Glance: Friday, November 8 32 Day-at-a-Glance: Saturday, November 9 50 Scientific Exposition 64 Exhibitor Spotlights 66 Day-at-a-Glance: Sunday, November 10 69 Attention US Physicians To ensure full compliance with the Open Payments (Physician Payments Sunshine Act), a provision of the Patient Protection and Affordable Care Act (PL 111-148), ASN reserves the right to provide information to applicable manufacturers and applicable GPOs about US physicians (and their spouses) who participate in selected ASN activities. Section 6002 of the Affordable Care Act requires the establishment of a transparency program, now known as Open Payments. The program increases public awareness of financial relationships between drug and device manufacturers and certain healthcare providers. ASN makes reasonable attempts to collect and maintain the following information about its US physician members: 1) name and business address, 2) specialty, 3) National Provider Identification (NPI) number, and 4) state(s) professional license number and name of state(s) issuing license. In the event that ASN receives payment from an applicable sponsor and the sponsor requests the reportable information from ASN, ASN will provide the information under the condition that the sponsor agrees to use the data only for reporting purposes covered under the Act and no other purpose. US physicians have certain rights under this Act, and more information about these rights can be found at the resources listed below. To learn more, please go to the US Government’s Center for Medicare & Medicaid Services (CMS) website (www.cms.gov/Regulations-and-Guidance/Legislation/National-Physician- Payment-Transparency-Program/Downloads/Physician-fact-sheet.pdf). Additional information can be found at the American Medical Association’s website (www.ama-assn.org/ama/pub/ advocacy/topics/sunshine-act-and-physician-financial-transparency-reports.page). American Society of Nephrology (ASN), www.ASN-online.org 1401 H Street, NW, Suite 900, Washington, DC, 20005 Copyright © 2019 ASN COMMUNITY LOUNGE EVENTS Make the most of your time at ASN Kidney Week with quick, informal sessions. Thursday 10:00 – 10:30 a.m. Continuous Renal Replacement Therapy Simulator Kamalanathan K. Sambandam, MD* Community Events 10:30 – 11:00 a.m. General & Clinical Nephrology Quick, informal Poster Tour Meet in the Lounge; Roger Rodby, MD, presentations by a FASN and Edgar Lerma, MD, FASN variety of experts. 11:00 – 11:30 a.m. Renal Pathology Web Episodes Timothy Yau, MD* Hear from: 12:00 – 12:30 p.m. Glomcom Trivia and • Past winners of the Case Conferences Innovations in Kidney Pravir V. Baxi, MD Education Contest 1:00 – 1:30 p.m. Leveraging Social Media for Your Career in Nephrology • Leading Joel Topf, MD nephrologists and Friday educators discussing a variety of topics 10:00 – 10:30 a.m. CRRT Virtual Patient Simulator Mobile App like social media in Benjamin Griffin, MD* nephrology 11:00 – 11:30 a.m. Navigating a Career in Medicine for Women in Nephrology • Experts like Dr. Rodby Silvi Shah, MD, MS, FASN and Dr. Lerma as 12:00 – 12:30 p.m. Hemodialysis Access 101 they lead you on an Namrata Krishnan, MD* exciting poster tour 1:00 – 1:30 p.m. Nephro360: Virtual Reality and Gaming Aleksandr Vasilyev, MD, PhD* Join an intimate Saturday group of your peers as you listen and partake 10:00 – 10:30 a.m. Why you should be reading Renal Fellow Network in conversations. Matt Sparks, MD, FASN 11:00 – 11:30 a.m. Q&A with the new Kidney360 Editor-in-Chief Michael Allon, MD, EIC 12:00 – 12:30 p.m. NephSIM Samira Farouk, MD, MS, FASN* 1:00 – 1:30 p.m. ASN Communities Mobile App Susan Willner, Manager, ASN Communities *Innovations in Kidney Education Contest Winners (2015-2018) COMMUNITY LOUNGE EVENTS 20 Make the most of your time at ASN Kidney Week 19 with quick, informal sessions. Washington, DC Nov. 5–10 Thursday Download the Kidney Week 10:00 – 10:30 a.m. Continuous Renal Replacement Therapy Simulator Kamalanathan K. Sambandam, MD* app now to get the most Community Events 10:30 – 11:00 a.m. General & Clinical Nephrology Quick, informal Poster Tour from your experience! Meet in the Lounge; Roger Rodby, MD, presentations by a FASN and Edgar Lerma, MD, FASN variety of experts. 11:00 – 11:30 a.m. Renal Pathology Web Episodes Timothy Yau, MD* Hear from: 12:00 – 12:30 p.m. Glomcom Trivia and ASN • Past winners of the Case Conferences Innovations in Kidney Pravir V. Baxi, MD Education Contest 1:00 – 1:30 p.m. Leveraging Social Media for Your Career in Nephrology • Leading Joel Topf, MD nephrologists and Friday Navigate the meeting like a pro educators discussing a variety of topics 10:00 – 10:30 a.m. CRRT Virtual Patient Simulator with the Kidney Week mobile app. Mobile App like social media in Benjamin Griffin, MD* • Stay organized with up-to-the- nephrology 11:00 – 11:30 a.m. Navigating a Career in Medicine minute session, exhibitor, and for Women in Nephrology meeting information • Experts like Dr. Rodby Silvi Shah, MD, MS, FASN and Dr. Lerma as • Receive important real-time 12:00 – 12:30 p.m. Hemodialysis Access 101 they lead you on an Namrata Krishnan, MD* communications from ASN exciting poster tour 1:00 – 1:30 p.m. Nephro360: Virtual Reality • Build a personalized schedule, and and Gaming bookmark exhibitors Aleksandr Vasilyev, MD, PhD* Join an intimate Saturday • Stay in-the-know, and join the group of your peers as social media dialogue you listen and partake 10:00 – 10:30 a.m. Why you should be reading And much, much more! Renal Fellow Network in conversations. Matt Sparks, MD, FASN 11:00 – 11:30 a.m. Q&A with the new Kidney360 Editor-in-Chief Michael Allon, MD, EIC 12:00 – 12:30 p.m. NephSIM The Kidney Week Mobile App Samira Farouk, MD, MS, FASN* GET THE FREE APP is supported by 1:00 – 1:30 p.m. ASN Communities Mobile App Susan Willner, Manager, ASN Communities *Innovations in Kidney Education Contest Winners (2015-2018) Schedule-at-a-Glance Thursday, November 7 AM 6:30 7:00 7:30 8:00 8:30 9:00 9:30 10:00 10:30 11:00 11:30 PM 12:00 12:30 1:00 1:30 2:00 2:30 3:00 3:30 4:00 4:30 5:00 5:30 6:00 6:30 7:00 Plenary Session BCSS, CPS, TS, SS Educational Symposia Oral Abstract Sessions Poster Sessions Ask the Author Welcome Scientific Exposition Exhibitor Spotlights Reception Friday, November 8 AM 6:30 7:00 7:30 8:00 8:30 9:00 9:30 10:00 10:30 11:00 11:30 PM 12:00 12:30 1:00 1:30 2:00 2:30 3:00 3:30 4:00 4:30 5:00 5:30 6:00 6:30 7:00 Plenary Session BCSS, CPS, TS, SS Educational Symposia Oral Abstract Sessions Poster Sessions Ask the Author Scientific Exposition Exhibitor Spotlights Saturday, November 9 AM 6:30 7:00 7:30 8:00 8:30 9:00 9:30 10:00 10:30 11:00 11:30 PM 12:00 12:30 1:00 1:30 2:00 2:30 3:00 3:30 4:00 4:30 5:00 5:30 6:00 6:30 7:00 Plenary Session BCSS, CPS, TS, SS Educational Symposia Oral Abstract Sessions Poster Sessions Ask the Author Scientific Exposition Exhibitor Spotlights Sunday, November 10 AM 6:30 7:00 7:30 8:00 8:30 9:00 9:30 10:00 10:30 11:00 11:30 PM 12:00 12:30 1:00 1:30 2:00 2:30 3:00 3:30 4:00 4:30 5:00 5:30 6:00 6:30 7:00 Plenary Session and ASN Business Meeting BCSS, CPS, TS, SS LEGEND BCSS - Basic/Clinical Science Sessions CPS - Clinical Practice Sessions TS - Translational Sessions SS - Special Sessions 4 Schedule-at-a-Glance Thursday, November 7 AM 6:30 7:00 7:30 8:00 8:30 9:00 9:30 10:00 10:30 11:00 11:30 PM 12:00 12:30 1:00 1:30 2:00 2:30 3:00 3:30 4:00 4:30 5:00 5:30 6:00 6:30 7:00 Plenary Session BCSS, CPS, TS, SS Educational Symposia Oral Abstract Sessions Poster Sessions Ask the Author Welcome Scientific Exposition Exhibitor Spotlights Reception Friday, November 8 AM 6:30 7:00 7:30 8:00 8:30 9:00 9:30 10:00 10:30 11:00 11:30 PM 12:00 12:30 1:00 1:30 2:00 2:30 3:00 3:30 4:00 4:30 5:00 5:30 6:00 6:30 7:00 Plenary Session BCSS, CPS, TS, SS Educational Symposia Oral Abstract Sessions High-Impact Clinical Trials Poster Sessions Ask the Author Scientific Exposition Exhibitor Spotlights Saturday, November 9 AM 6:30 7:00 7:30 8:00 8:30 9:00 9:30 10:00 10:30 11:00 11:30 PM 12:00 12:30 1:00 1:30 2:00 2:30 3:00 3:30 4:00 4:30 5:00 5:30 6:00 6:30 7:00 Plenary Session BCSS, CPS, TS, SS Educational Symposia Oral Abstract Sessions Poster Sessions Ask the Author Scientific Exposition Exhibitor Spotlights Sunday, November 10 AM 6:30 7:00 7:30 8:00 8:30 9:00 9:30 10:00 10:30 11:00 11:30 PM 12:00 12:30 1:00 1:30 2:00 2:30 3:00 3:30 4:00 4:30 5:00 5:30 6:00 6:30 7:00 Plenary Session and ASN Business Meeting BCSS, CPS, TS, SS 5 Welcome to ASN Kidney Week Bringing Discovery to People with Kidney Diseases ASN proudly welcomes you to Kidney Week, the world’s premier nephrology meeting.
Load more

Recommended publications
  • Hypothermic Oxygenated Perfusion Versus Static Cold Storage For
    JMIR RESEARCH PROTOCOLS Ravaioli et al Protocol Hypothermic Oxygenated Perfusion Versus Static Cold Storage for Expanded Criteria Donors in Liver and Kidney Transplantation: Protocol for a Single-Center Randomized Controlled Trial Matteo Ravaioli1, MD, PhD, Prof Dr; Lorenzo Maroni1, MD; Andrea Angeletti2, MD; Guido Fallani1, MD; Vanessa De Pace1, MS; Giuliana Germinario1, MS; Federica Odaldi1, MD; Valeria Corradetti2, MD; Paolo Caraceni1, MD, Prof Dr; Maurizio Baldassarre1, MS, PhD; Francesco Vasuri3, MD, PhD; Antonia D©Errico3, MD, Prof Dr; Gabriela Sangiorgi4, MD; Antonio Siniscalchi1, MD; Maria Cristina Morelli1, MD; Anna Rossetto1, MD; Vito Marco Ranieri1, Prof Dr; Matteo Cescon1, MD, PhD, Prof Dr; Massimo Del Gaudio1, MD, PhD; Chiara Zanfi1, MD; Valentina Bertuzzo1, MD, PhD; Giorgia Comai2, MD, PhD; Gaetano La Manna2, MD, PhD, Prof Dr 1Department of Medical and Surgical Sciences, University of Bologna Sant©Orsola-Malpighi Hospital, Bologna, Italy 2Department of Experimental Diagnostic and Specialty Medicine, University of Bologna Sant©Orsola-Malpighi Hospital, Bologna, Italy 3Pathology Division, University of Bologna Sant©Orsola-Malpighi Hospital, Bologna, Italy 4Emilia-Romagna Transplantation Referral Center, Emilia-Romagna, Italy Corresponding Author: Matteo Ravaioli, MD, PhD, Prof Dr Department of Medical and Surgical Sciences University of Bologna Sant©Orsola-Malpighi Hospital Via Massarenti, 9 Bologna, 40138 Italy Phone: 39 051 2144810 Email: [email protected] Abstract Background: Extended criteria donors (ECD) are widely utilized due to organ shortage, but they may increase the risk of graft dysfunction and poorer outcomes. Hypothermic oxygenated perfusion (HOPE) is a recent organ preservation strategy for marginal kidney and liver grafts, allowing a redirect from anaerobic metabolism to aerobic metabolism under hypothermic conditions and protecting grafts from oxidative species±related damage.
    [Show full text]
  • Endothelin System and Therapeutic Application of Endothelin Receptor
    xperim ACCESS Freely available online & E en OPEN l ta a l ic P in h l a C r m f o a c l a o n l o r g u y o J Journal of ISSN: 2161-1459 Clinical & Experimental Pharmacology Research Article Endothelin System and Therapeutic Application of Endothelin Receptor Antagonists Abebe Basazn Mekuria, Zemene Demelash Kifle*, Mohammedbrhan Abdelwuhab Department of Pharmacology, School of Pharmacy, College of Medicine and Health Sciences, University of Gondar, Gondar, Ethiopia ABSTRACT Endothelin is a 21 amino acid molecule endogenous potent vasoconstrictor peptide. Endothelin is synthesized in vascular endothelial and smooth muscle cells, as well as in neural, renal, pulmonic, and inflammatory cells. It acts through a seven transmembrane endothelin receptor A (ETA) and endothelin receptor B (ETB) receptors belongs to G protein-coupled rhodopsin-type receptor superfamily. This peptide involved in pathogenesis of cardiovascular disorder like (heart failure, arterial hypertension, myocardial infraction and atherosclerosis), renal failure, pulmonary arterial hypertension and it also involved in pathogenesis of cancer. Potentially endothelin receptor antagonist helps the treatment of the above disorder. Currently, there are a lot of trails both per-clinical and clinical on endothelin antagonist for various cardiovascular, pulmonary and cancer disorder. Some are approved by FAD for the treatment. These agents are including both selective and non-selective endothelin receptor antagonist (ETA/B). Currently, Bosentan, Ambrisentan, and Macitentan approved
    [Show full text]
  • Label-Free Proteomic Methodology for the Analysis of Human Kidney Stone Matrix Composition Frank A
    Witzmann et al. Proteome Science (2016) 14:4 DOI 10.1186/s12953-016-0093-x METHODOLOGY Open Access Label-free proteomic methodology for the analysis of human kidney stone matrix composition Frank A. Witzmann1*, Andrew P. Evan2, Fredric L. Coe3, Elaine M. Worcester3, James E. Lingeman4 and James C. Williams Jr2 Abstract Background: Kidney stone matrix protein composition is an important yet poorly understood aspect of nephrolithiasis. We hypothesized that this proteome is considerably more complex than previous reports have indicated and that comprehensive proteomic profiling of the kidney stone matrix may demonstrate relevant constitutive differences between stones. We have analyzed the matrices of two unique human calcium oxalate stones (CaOx-Ia and CaOx-Id) using a simple but effective chaotropic reducing solution for extraction/solubilization combined with label-free quantitative mass spectrometry to generate a comprehensive profile of their proteomes, including physicochemical and bioinformatic analysis.` Results: We identified and quantified 1,059 unique protein database entries in the two human kidney stone samples, revealing a more complex proteome than previously reported. Protein composition reflects a common range of proteins related to immune response, inflammation, injury, and tissue repair, along with a more diverse set of proteins unique to each stone. Conclusion: The use of a simple chaotropic reducing solution and moderate sonication for extraction and solubilization of kidney stone powders combined with label-free quantitative mass spectrometry has yielded the most comprehensive list to date of the proteins that constitute the human kidney stone proteome. Keywords: Calcium oxalate, Kidney stone, Label-free quantitative liquid chromatography–tandem mass spectrometry, Matrix protein, Nephrolithiasis, Proteomics Background deposition is the primary event, at least in the formation The organic matrix within urinary stones has long been of CaOx stones over plaque.
    [Show full text]
  • FY 2020 Results Conference Call and Webcast for Investors and Analysts
    FY 2020 results Conference call and webcast for investors and analysts 11 February 2021 Forward-looking statements In order, among other things, to utilise the 'safe harbour' provisions of the US Private Securities Litigation Reform Act of 1995, AstraZeneca (hereafter ‘the Group’) provides the following cautionary statement: this document contains certain forward-looking statements with respect to the operations, performance and financial condition of the Group, including, among other things, statements about expected revenues, margins, earnings per share or other financial or other measures. Although the Group believes its expectations are based on reasonable assumptions, any forward-looking statements, by their very nature, involve risks and uncertainties and may be influenced by factors that could cause actual outcomes and results to be materially different from those predicted. The forward-looking statements reflect knowledge and information available at the date of preparation of this document and the Group undertakes no obligation to update these forward-looking statements. The Group identifies the forward-looking statements by using the words 'anticipates', 'believes', 'expects', 'intends' and similar expressions in such statements. Important factors that could cause actual results to differ materially from those contained in forward-looking statements, certain of which are beyond the Group’s control, include, among other things: the risk of failure or delay in delivery of pipeline or launch of new medicines; the risk of failure
    [Show full text]
  • Zibotentan, an Endothelin a Receptor Antagonist, Prevents Amyloid-Я
    Journal of Alzheimer’s Disease 73 (2020) 1185–1199 1185 DOI 10.3233/JAD-190630 IOS Press Zibotentan, an Endothelin A Receptor Antagonist, Prevents Amyloid-␤-Induced Hypertension and Maintains Cerebral Perfusion Jennifer C. Palmera,1, Hannah M. Taylera,1, Laurence Dyera, Patrick G. Kehoea, Julian F.R. Patonb and Seth Lovea,∗ aTranslational Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK bDepartment of Physiology, Faculty of Medical & Health Sciences, University of Auckland, New Zealand Accepted 25 November 2019 Abstract. Cerebral blood flow is reduced in Alzheimer’s disease (AD), which is associated with mid-life hypertension. In people with increased cerebral vascular resistance due to vertebral artery or posterior communicating artery hypoplasia, there is evidence that hypertension develops as a protective mechanism to maintain cerebral perfusion. In AD, amyloid-␤ (A␤) accumulation may similarly raise cerebral vascular resistance by upregulation of the cerebral endothelin system. The level of endothelin-1 in brain tissue correlates positively with A␤ load and negatively with markers of cerebral hypoperfusion such as increased vascular endothelial growth factor. We previously showed that cerebroventricular infusion of A␤40 exacerbated pre- existing hypertension in Dahl rats. We have investigated the effects of 28-day cerebral infusion of A␤40 on blood pressure and heart rate and their variability; carotid flow; endothelin-1; and markers of cerebral oxygenation, in the (normotensive) Wistar rat, and the modulatory influence of the endothelin A receptor antagonist Zibotentan (ZD4054). Cerebral infusion of A␤ caused progressive rise in blood pressure (p < 0.0001) (paired t-test: increase of 3 (0.1–5.6) mmHg (p = 0.040)), with evidence of reduced baroreflex responsiveness, and accumulation of A␤ and elevated endothelin-1 in the vicinity of the infusion.
    [Show full text]
  • Ischemia-Reperfusion Injuries Assessment During Pancreas Preservation
    International Journal of Molecular Sciences Review Ischemia-Reperfusion Injuries Assessment during Pancreas Preservation Thomas Prudhomme 1,2 , John F. Mulvey 3 , Liam A. J. Young 3,4 , Benoit Mesnard 1,2 , Maria Letizia Lo Faro 3, Ann Etohan Ogbemudia 3, Fungai Dengu 3, Peter J. Friend 3, Rutger Ploeg 3, James P. Hunter 3 and Julien Branchereau 1,2,3,* 1 Institut de Transplantation Urologie Néphrologie (ITUN), CHU Nantes, 44000 Nantes, France; [email protected] (T.P.); [email protected] (B.M.) 2 Centre de Recherche en Transplantation et Immunologie (CRTI) UMR1064, INSERM, Université de Nantes, 44000 Nantes, France 3 Nuffield Department of Surgical Sciences, University of Oxford, Oxford OX3 9DU, UK; [email protected] (J.F.M.); [email protected] (L.A.J.Y.); [email protected] (M.L.L.F.); [email protected] (A.E.O.); [email protected] (F.D.); [email protected] (P.J.F.); [email protected] (R.P.); [email protected] (J.P.H.) 4 Oxford Centre for Clinical Magnetic Resonance Research (OCMR), Radcliffe Department of Medicine, University of Oxford, Oxford OX3 9DU, UK * Correspondence: [email protected] Abstract: Maintaining organ viability between donation and transplantation is of critical importance for optimal graft function and survival. To date in pancreas transplantation, static cold storage (SCS) Citation: Prudhomme, T.; Mulvey, is the most widely practiced method of organ preservation. The first experiments in ex vivo perfusion J.F.; Young, L.A.J.; Mesnard, B.; Lo of the pancreas were performed at the beginning of the 20th century.
    [Show full text]
  • Experimental Models of Prostate Cancer Bone Metastasis - Establishment, Characterization and Imaging of Xenograft Bone Metastasis Models
    Experimental Models of Prostate Cancer Bone Metastasis - Establishment, characterization and imaging of xenograft bone metastasis models - PhD thesis presented by Marta Garcia López To obtain the degree of PhD for the Universitat Autònoma de Barcelona (UAB) PhD thesis done at the Research Unit in Biomedicine and Translational and Pediatrics Oncology, at the Vall d’Hebron Research Institute, Vall d’Hebron Hospital, under the supervision of Drs. Jaume Reventós i Puigjaner, Andreas Doll and Juan Morote Robles Doctoral study in Biochemistry, Molecular Biology and Biomedicine. Universitat Autònoma de Barcelona, Faculty of Bioscience, Department of Biochemistry and Molecular Biology Universitat Autònoma de Barcelona, 2013 Dr. Jaume Reventós Puigjaner Dr. Andreas Doll Dr. Juan Morote Robles Marta Garcia López No entiendes realmente algo a menos que seas capaz de explicárselo a tu abuela. Albert Einstein Summary In industrialized countries, prostate cancer (PCa) is the most common malignancy in men, but mortality rates are much lower than those recorded in developing countries, reflecting benefits from advances in early diagnosis and effective treatment. However, the metastatic disease rather than the primary tumour is responsible for much of the resulting morbidity and mortality. Skeletal metastases occur in more than 70% of cases of late-stage of PCa and they confer a high level of morbidity, a 5-year survival rate of 25% and median survival of approximately 40 months. Though fractures and spinal cord compression are potential complications, the most common symptom of bone metastases is pain. Bone metastases from PCa lead to an accelerated bone turnover state that features pathological activation of both osteoblasts and osteoclasts.
    [Show full text]
  • Tanibirumab (CUI C3490677) Add to Cart
    5/17/2018 NCI Metathesaurus Contains Exact Match Begins With Name Code Property Relationship Source ALL Advanced Search NCIm Version: 201706 Version 2.8 (using LexEVS 6.5) Home | NCIt Hierarchy | Sources | Help Suggest changes to this concept Tanibirumab (CUI C3490677) Add to Cart Table of Contents Terms & Properties Synonym Details Relationships By Source Terms & Properties Concept Unique Identifier (CUI): C3490677 NCI Thesaurus Code: C102877 (see NCI Thesaurus info) Semantic Type: Immunologic Factor Semantic Type: Amino Acid, Peptide, or Protein Semantic Type: Pharmacologic Substance NCIt Definition: A fully human monoclonal antibody targeting the vascular endothelial growth factor receptor 2 (VEGFR2), with potential antiangiogenic activity. Upon administration, tanibirumab specifically binds to VEGFR2, thereby preventing the binding of its ligand VEGF. This may result in the inhibition of tumor angiogenesis and a decrease in tumor nutrient supply. VEGFR2 is a pro-angiogenic growth factor receptor tyrosine kinase expressed by endothelial cells, while VEGF is overexpressed in many tumors and is correlated to tumor progression. PDQ Definition: A fully human monoclonal antibody targeting the vascular endothelial growth factor receptor 2 (VEGFR2), with potential antiangiogenic activity. Upon administration, tanibirumab specifically binds to VEGFR2, thereby preventing the binding of its ligand VEGF. This may result in the inhibition of tumor angiogenesis and a decrease in tumor nutrient supply. VEGFR2 is a pro-angiogenic growth factor receptor
    [Show full text]
  • Utilizing Animal Studies to Evaluate Organ Preservation Devices ______Guidance for Industry and Food and Drug Administration Staff
    Contains Nonbinding Recommendations Utilizing Animal Studies to Evaluate Organ Preservation Devices ______________________________________________________________________________ Guidance for Industry and Food and Drug Administration Staff Document issued on May 8, 2019. The draft of this document was issued on September 15, 2017. For questions about this document, contact DHT3A: Division of Renal, Gastrointestinal, Obesity, and Transplant Devices at 301-796-7030. U.S. Department of Health and Human Services Food and Drug Administration Center for Devices and Radiological Health Contains Nonbinding Recommendations Preface Public Comment You may submit electronic comments and suggestions at any time for Agency consideration to https://www.regulations.gov. Submit written comments to the Dockets Management Staff, Food and Drug Administration, 5630 Fishers Lane, Room 1061, (HFA-305), Rockville, MD 20852. Identify all comments with the docket number FDA-2017-D-4886. Comments may not be acted upon by the Agency until the document is next revised or updated. Additional Copies Additional copies are available from the Internet. You may also send an e-mail request to [email protected] to receive a copy of the guidance. Please use the document number 1500083 to identify the guidance you are requesting. Contains Nonbinding Recommendations Table of Contents I. Introduction ........................................................................................................................... 1 II. Scope ....................................................................................................................................
    [Show full text]
  • Uromodulin Levels Associate with a Common UMOD Variant and Risk for Incident CKD
    CLINICAL EPIDEMIOLOGY www.jasn.org Uromodulin Levels Associate with a Common UMOD Variant and Risk for Incident CKD ʈ ʈ Anna Ko¨ttgen,* Shih-Jen Hwang,†‡ Martin G. Larson,§ Jennifer E. Van Eyk, Qin Fu, Emelia J. Benjamin,†¶ Abbas Dehghan,** Nicole L. Glazer,†† W.H. Linda Kao,* ʈʈ Tamara B. Harris,‡‡ Vilmundur Gudnason,§§ Michael G. Shlipak,¶¶ Qiong Yang,§ Josef Coresh,* Daniel Levy,†‡ and Caroline S. Fox†‡*** *Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland; †Framingham Heart Study, Framingham, Massachusetts; ‡Center for Population Studies, National Heart, Lung, and Blood Institute, and ‡‡Laboratory of Epidemiology, Demography, and Biometry, Intramural Research Program, National Institute on Aging, National Institutes of Health, Bethesda, Maryland; Departments of §Biostatistics and ʈ ¶Epidemiology, Boston University School of Public Health, Boston, Massachusetts; Department of Medicine, Johns Hopkins University, Baltimore, Maryland; **Department of Epidemiology, Erasmus Medical Centre, Rotterdam, Netherlands; ††Cardiovascular Health Research Unit and Department of Medicine, University of Washington, Seattle, ʈʈ Washington; §§Icelandic Heart Association Research Institute, Kopavogur, Iceland; University of Iceland, Reykjavik, Iceland; ¶¶General Internal Medicine Division, San Francisco VA Medical Center, University of California, San Francisco, California; and ***Division of Endocrinology, Metabolism, and Diabetes, Department of Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, Massachusetts ABSTRACT Common variants in the region of the UMOD gene, which encodes uromodulin (Tamm-Horsfall protein), associate with chronic kidney disease (CKD) and estimated GFR (eGFR). Whether uromodulin levels associate with UMOD variants or with the risk for developing CKD is unknown. We conducted an age- and gender- matched case-control study (n ϭ 200) of incident CKD (eGFR Ͻ60 ml/min per 1.73 m2) within the Framingham Heart Study (FHS).
    [Show full text]
  • Characterisation of Proendothelin-1 Derived Peptides and Evaluation of Their Utility As Biomarkers of Vascular and Renal Pathologies
    Characterisation of Proendothelin-1 Derived Peptides and Evaluation of Their Utility as Biomarkers of Vascular and Renal Pathologies Jale Yuzugulen A thesis submitted for the degree of Doctor of Philosophy (Ph.D) in the Barts and the London School of Medicine and Dentistry of the Queen Mary, University of London 2014 Centre for Translational Medicine & Therapeutics, William Harvey Research Institute, John Vane Science Centre Charterhouse Square London UK i Statement of originality I, Jale Yuzugulen, confirm that the research included within this thesis is my own work or that where it has been carried out in collaboration with, or supported by others, that this is duly acknowledged below and my contribution indicated. Previously published material is also acknowledged below. I attest that I have exercised reasonable care to ensure that the work is original, and does not to the best of my knowledge break any UK law, infringe any third party’s copyright or other Intellectual Property Right, or contain any confidential material. I accept that the College has the right to use plagiarism detection software to check the electronic version of the thesis. I confirm that this thesis has not been previously submitted for the award of a degree by this or any other university. The copyright of this thesis rests with the author and no quotation from it or information derived from it may be published without the prior written consent of the author. Signature: [ ] Date: 10/03/2014 ii List of publications and abstracts arising from this thesis: 1. Yuzugulen J, Wood EG, Douthwaite JA, Villar IC, Patel NS, Jegard J, Montoya A, Cutillas P, Hartley O, Ahluwalia A, Corder R.
    [Show full text]
  • Mitochondrial Targeting Therapy Role in Liver Transplant Preservation Lines: Mechanism and Therapeutic Strategies
    Open Access Review Article DOI: 10.7759/cureus.16599 Mitochondrial Targeting Therapy Role in Liver Transplant Preservation Lines: Mechanism and Therapeutic Strategies Anjli Tara 1, 2 , Jerry Lorren Dominic 3, 4, 5, 1 , Jaimin N. Patel 6 , Ishan Garg 7 , Jimin Yeon 7 , Marrium S. Memon 8 , Sanjay Rao Gergal Gopalkrishna Rao 9 , Seif Bugazia 10 , Tamil Poonkuil Mozhi Dhandapani 11, 12 , Amudhan Kannan 13, 14 , Ketan Kantamaneni 15, 16 , Myat Win 17, 1 , Terry R. Went 15 , Vijaya Lakshmi Yanamala 15 , Jihan A. Mostafa 18 1. General Surgery, California Institute of Behavioral Neurosciences & Psychology (CIBNP), Fairfield, USA 2. General Surgery, Liaquat University of Medical and Health Sciences (LUMHS), Jamshoro, PAK 3. General Surgery, Vinayaka Mission's Kirupananda Variyar Medical College, Salem, IND 4. General Surgery, Stony Brook Southampton Hospital, New York, USA 5. General Surgery and Orthopaedic Surgery, Cornerstone Regional Hospital, Edinburg, USA 6. Family Medicine, California Institute of Behavioral Neurosciences & Psychology (CIBNP), Fairfield, USA 7. Medicine, California Institute of Behavioral Neurosciences & Psychology (CIBNP), Fairfield, USA 8. Research, California Institute of Behavioral Neurosciences & Psychology (CIBNP), Fairfield, USA 9. Internal Medicine, California Institute of Behavioral Neurosciences & Psychology (CIBNP), Fairfield, USA 10. Faculty of Medicine, California Institute of Behavioral Neurosciences & Psychology (CIBNP), Fairfield, USA 11. Internal Medicine/Family Medicine, California Institute of Behavioral Neuroscience & Pyshology (CIBNP), Fairfield, USA 12. Internal Medicine, Medical City Plano, Plano, USA 13. Medicine, Jawaharlal Institute of Postgraduate Medical Education and Research (JIPMER), Puducherry, IND 14. General Surgery Research, California Institute of Behavioral Neurosciences & Psychology (CIBNP), Fairfield, USA 15. Surgery, California Institute of Behavioral Neurosciences & Psychology (CIBNP), Fairfield, USA 16.
    [Show full text]